SKYE stock forecast
Information about the stock market for Skye Bioscience Inc. (SKYE)
Skye Bioscience Inc is a stock on the US market. The price is now 4.25 USD, which is a change of 0.56 USD (0.15%) from the last closure. The most recent open price was $3.76, and the volume for the day so far is 2,216,540. The highest price throughout the day is 4.65 USD, and the lowest price is 3.59 USD. The most recent deal was placed on Friday, June 27, 05:45:00 +0530.
This 600-word projection for Skye Bioscience Inc. (SKYE) looks at the company’s present fundamentals and makes long-term stock predictions for 2025 to 2040.
📊 Current Basics (June 2025)
| Metric | Value |
|---|---|
| Market Cap | ~$112–132 M USD ([stockanalysis.com][1], [gurufocus.com][2]) |
| P/E Ratio (TTM) | N/A (negative earnings) |
| Return on Equity | ~–47% |
| Price-to-Book (P/B) | ~2.2× |
Skye Bioscience is a clinical-stage biotech company that isn’t making any money right now. It has big operational losses (about $32 million), negative PE ratios, a small balance sheet, and a liquidity buffer (current ratio of around 11 times). ([fullratio.com][3])
🔮 SKYE Stock Predictions
SKYE stock forecast 2025
Skye moves on with nimacimab studies with backend CB1 data; advancement in Phase IIa (CBeyond) might lead to one or two catalysts. Analysts think there will be $8–12M milestones and that institutions will keep supporting the project.
Goal for 2025: $8
SKYE stock forecast 2026
With a possible Phase II topline publication, the results may either confirm the pipeline or lead to a reassessment. The next medication candidate IND submission and successful CB1 results are very important.
2026 Target: $15
SKYE stock forecast 2027
If the findings of nimacimab are good, SKYE will go on to Phase III studies with more money or partnerships, which might include licensing arrangements with big pharmaceutical companies.
Goal for 2027: $25
SKYE stock forecast 2028
Possible partnerships or licenses with a significant partner contribute to upfront payments that raise the value. You may add a second IND for a pipeline candidate.
2028 Goal: $40
SKYE stock forecast 2029
Enrollment for Phase III starts; more applicants might raise the company’s value. Costs for research and development start to level off.
2029 Goal: $60
SKYE stock forecast 2030
Enrollment is done, and important data might be available around late 2030. The approval process starts, and there may be a breakthrough designation from the FDA and tech leverage.
Goal for 2030: $90
SKYE stock forecast 2031
If nimacimab is approved, partnerships or specialized suppliers will start making it before it goes on sale and will start bringing in money.
2031 Goal: $150
SKYE stock forecast 2032
The first commercial launch and royalty money contribute to the revenue stream. If nimacimab works, it might go into the obesity and comorbidity market.
2032 Goal: $220
SKYE stock forecast 2033
There is a chance of pipeline growth, since there are signs of expansion or next-gen molecules like SKYE-xxx in Phase I development. The magnitude of revenue goes up.
2033 Goal: $300
SKYE stock forecast 2034
Revenue keeps going up and may reach $50 million or more from sales; gross margins go up and investors feel more confident.
2034 Goal: $400
SKYE stock forecast 2035
Geographic growth (to the EU and Asia), label expansions, and successful mid-stage assets should all help mid- to large-cap value multiples.
2035 Goal: $600
SKYE stock forecast 2036
A lot of money comes in from nimacimab and the next-gen asset. R&D capital efficiency and the fact that Phase III is about to start in more indications.
2036 Goal: $800
SKYE stock forecast 2037
Major analysts raise their ratings once the company does well in business; there may be interest in biotech M&A. The cash flow goes up.
2037 Goal: $1,000
SKYE stock forecast 2038
As product royalties grow and the pipeline becomes deeper, the business becomes a lucrative biotech that focuses on pathogens and CB1 and has several streams of income.
2038 Goal: $1,200
SKYE stock forecast 2039
Valuation growth comes from sustainable profits. SKYE is a mid-cap biotech company. Early-stage R&D goes to the clinic to get a new asset.
2039 Goal: $1,400
SKYE stock forecast 2040
Nimacimab will be fully commercialized for a number of uses. A growing pipeline and the chance of a transaction or takeover with Big Pharma.
2040 Target: $1,600
📈 Yearly Price Targets Table
| Year | Target (USD) |
|---|---|
| 2025 | 8 |
| 2026 | 15 |
| 2027 | 25 |
| 2028 | 40 |
| 2029 | 60 |
| 2030 | 90 |
| 2031 | 150 |
| 2032 | 220 |
| 2033 | 300 |
| 2034 | 400 |
| 2035 | 600 |
| 2036 | 800 |
| 2037 | 1,000 |
| 2038 | 1,200 |
| 2039 | 1,400 |
| 2040 | 1,600 |
🚀 Important Factors for Growth
- Nimacimab Phase II/III results — good data will make the value go up.
- Expansion of the clinical pipeline — new assets provide a wider view of value.
- Partnerships and licensing — big pharma agreements speed up expansion.
- Regulatory milestones, including getting FDA breakthrough status.
- Commercial launch — setting up the supply chain and sales support.
- Revenue ramp — the change from a research and development firm to one that makes money.
⚠️ Risks and Things to Think About
- If a clinical study fails, the value might go down a lot.
- High risk of dilution from funding.
- Changes in the biotech industry are connected to news about pipelines.
- Regulatory or procedural problems might slow down the process of bringing a product to market.
📝 End
Skye Bioscience is a biotech-stage company with a lot of risk, but it might make a lot of money from nimacimab and other pipeline discoveries. If SKYE does well in Phase III and is able to sell its products, it might become a mid-cap biotech worth billions of dollars. But there are still big risks in terms of clinical, financial, and implementation.